November 2025
1. SELLERS ZM, Cohen AH
   Challenges and opportunities for drug development in rare pulmonary diseases like cystic fibrosis: an industry perspective.
   Curr Opin Pulm Med. 2025;31:658-665.
   

   >> Share

   
   
2. MARTIN I, Ratjen F, Flume P
   Evolving cystic fibrosis care models in the modulator era.
   Curr Opin Pulm Med. 2025;31:644-649.
   

   >> Share

   
   September 2025
3. TOLLE J, O'Connor M
   Bronchiectasis evaluation 2025: pediatric and adult perspectives.
   Curr Opin Pulm Med. 2025 Sep 8. doi: 10.1097/MCP.0000000000001217.
   

   >> Share

   
   
4. MASSEY J, Haidar G, Shields RK, Van Tyne D, et al
   New anti-infective approaches to treat airway infections in persons with cystic fibrosis and bronchiectasis.
   Curr Opin Pulm Med. 2025 Sep 4. doi: 10.1097/MCP.0000000000001214.
   

   >> Share

   
   July 2025
5. VAN DER PLOEG EA, Hylkema TH, Gan CT
   Timing of lung transplant evaluation: considerations, barriers and alternatives.
   Curr Opin Pulm Med. 2025;31:354-358.
   

   >> Share

   
   November 2024
6. TAYLOR-COUSAR JL, Sole A, Jain R
   Pregnancy and fertility in people with cystic fibrosis following lung transplantation.
   Curr Opin Pulm Med. 2024;30:652-659.
   

   >> Share

   
   
7. WESTHOFF J, Naehrlich L
   Epidemiology of advanced cystic fibrosis lung disease in the modulator era.
   Curr Opin Pulm Med. 2024;30:633-639.
   

   >> Share

   
   
8. MCLAFFERTY FS, Gray AL
   Lung transplant referral considerations for individuals with cystic fibrosis.
   Curr Opin Pulm Med. 2024;30:640-645.
   

   >> Share

   
   
9. KAPNADAK SG, Ramos KJ
   Elexacaftor-tezacaftor-ivacaftor use after solid organ transplant.
   Curr Opin Pulm Med. 2024;30:660-666.
   

   >> Share

   
   
10. AVDIMIRETZ N, Halloran K, Benden C
    Outcomes of lung transplantation in cystic fibrosis.
    Curr Opin Pulm Med. 2024;30:646-651.
    

    >> Share

    
    September 2024
11. EICHSTAEDT CA, Haas SO, Shaukat M, Grunig E, et al
    Genetic background of pulmonary (vascular) diseases - how much is written in the codes?
    Curr Opin Pulm Med. 2024;30:429-436.
    

    >> Share

    
    November 2023
12. VANELZAKKER MB, Tillman EM, Yonker LM, Ratai EM, et al
    Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort.
    Curr Opin Pulm Med. 2023;29:603-609.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share